Clinical Trials Directory

Trials / Unknown

UnknownNCT05071911

Targeted Axillary Dissection After Neo-adjuvant Chemotherapy

Feasability Study of a New Technique of Axillary Evaluation in Patients With Node Positive Breast Cancer Following Neo-adjuvant Chemotherapy

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Universitair Ziekenhuis Brussel · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Currently most breast cancer patients with confirmed axillary lymph node metastasis (cN1) at diagnosis are candidates for neoadjuvant chemotherapy (NAC). The increased utilization of NAC can be attributed to practical clinical advantages. The increasing use of NAC has, however, introduced questions regarding appropriate loco-regional management, including the optimal surgical approach to the axillary lymph nodes. According to current guidelines, patients presenting with cN1 disease and treated with NAC, still undergo axillary lymph node dissection (ALND). In forty percent of these patients, however, the investigators see a nodal complete pathological response (ypN0). In certain subgroups, triple negative breast cancer and Her2 amplified breast cancer, this percentage is even higher. The investigators would like to lessen surgical morbidity by performing a targeted axillary dissection. The investigators place a clip in the biopsy-proven lymph node metastasis at diagnosis. After NAC, the investigators perform a dual agent sentinel node procedure and remove the clipped node during the same surgery. When these lymph nodes are microscopically tumor-free, the investigators can abolish an ALND. Targeted axillary dissection after NAC for cN1 disease seems to have acceptable false negative rates in previous trials. The investigators would like to further define patients where an ALND can be safely omitted.

Conditions

Interventions

TypeNameDescription
PROCEDURETAD (Targeted Axillary Dissection)Dual agent SLNB + resection of proven lymph nodes metastasis marked with clip at diagnosis

Timeline

Start date
2021-04-21
Primary completion
2024-06-01
Completion
2024-06-01
First posted
2021-10-08
Last updated
2023-11-07

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT05071911. Inclusion in this directory is not an endorsement.